AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more
AN2 Therapeutics Inc (ANTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.106x
Based on the latest financial reports, AN2 Therapeutics Inc (ANTX) has a cash flow conversion efficiency ratio of -0.106x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.38 Million) by net assets ($60.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AN2 Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how AN2 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AN2 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AN2 Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sao Ta Foods JSC
VN:FMC
|
0.266x |
|
D4t4 Solutions Plc
PINK:DFORF
|
-0.033x |
|
Panca Anugrah Wisesa Tbk PT
JK:MGLV
|
-0.031x |
|
HYUNDAI FEED Inc
KQ:016790
|
0.015x |
|
DFI Inc
TW:2397
|
0.005x |
|
Taiga Building Products Ltd
PINK:TGAFF
|
0.253x |
|
Zespol Elektrowni Patnow Adamow Konin SA
WAR:ZEP
|
0.081x |
|
Hotron Precision Electronic Industrial Co Ltd
TW:3092
|
-0.048x |
Annual Cash Flow Conversion Efficiency for AN2 Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of AN2 Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $81.85 Million | $-49.26 Million | -0.602x | -40.83% |
| 2023-12-31 | $124.70 Million | $-53.29 Million | -0.427x | -21.79% |
| 2022-12-31 | $95.37 Million | $-33.46 Million | -0.351x | -6.04% |
| 2021-12-31 | $61.91 Million | $-20.48 Million | -0.331x | +83.03% |
| 2020-12-31 | $2.75 Million | $-5.36 Million | -1.950x | -277.50% |
| 2019-12-31 | $4.81 Million | $-2.49 Million | -0.517x | -- |